We've closed a $48.5M #SeriesA financing round. This funding supports our #PremarketApproval submission for the #ReviventTC, expanding access to allow additional procedures. We've also appointed Raphael Wisniewski & Bihua Chen to our Board of Directors: https://t.co/4zyrg6sYZN
#THT2023 is over! Thank you to the @CRFHeart for a great event. We also want to thank all those who joined us for our lunch symposium. If you didn't get a chance to meet with us at THT, set up a meeting at https://t.co/slVRypGJxr. #heartfailure#interventionalcardiology
Hello Boston! We are excited about our lunch symposium today and can't wait to meet and discuss the next frontier in interventional heart failure. Take a look at our program at https://t.co/180V4QIe2f.
We hope to see you there!
#THT2023#HeartFailure#InterventionalCardiology
#THT2023 is just days away. Join us at the BioVentrix Lunch Symposium where we'll discuss The Left Ventricle: Interventional Heart Failure's Next Frontier.
Contact us today to learn more: https://t.co/UVN22TtHTi. #HeartFailure#InterventionalCardiology
We are excited to announce distinguished #cardiologist Ori Ben-Yehuda, MD, as our new Chief Medical Officer. With years of experience in the field, he will play a critical role to our team as we move into the advanced stages of #PremarketApproval: https://t.co/e91x0EVfes
Our Revivent TC System has been approved by the FDA for an Expanded Access Program. This procedure is designed to treat dilated left ventricles in patients with ischemic #heartfailure & extensive scarring who have not responded well to traditional therapy. https://t.co/4v5pR9vi1E
Thank you to everyone who attended the Heart Failure Innovation – Reshaping the LV as a Treatment for Heart Failure event, 5 PM Sunday, 9/18, Innovation Theatre, Rm 210
Visit BioVentrix, Booth #353.
#StructuralHeart#LVreshape#ReviventTC@cardiovascular-research-foundation